{"entity":{"id":"guangzhou-virotech","kind":"company","name":"Guangzhou Virotech Pharmaceutical","aka":["Guangzhou Virotech Pharmaceutical Co., Ltd."],"tldr":"Guangzhou Virotech Pharmaceutical is a China-based biotechnology company that leads 2 cancer trials in OnCo, testing the M1 alphavirus-based oncolytic virus VRT106 in glioma & glioblastoma and diffuse midline glioma, H3 K27-altered.","summary":"Guangzhou Virotech Pharmaceutical is a Guangzhou-based biopharmaceutical company. The ClinicalTrials.gov registry lists it as lead sponsor of trials of intravenously administered oncolytic virus therapies based on the M1 alphavirus, including VRT106 (M1-c6v1), in advanced solid tumours and gliomas. No company website could be verified, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07093814 (phase 1/2, A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma) and NCT07589257 (phase 2, A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midli...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov: trials led by Guangzhou Virotech Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Guangzhou%20Virotech%20Pharmaceutical%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma","dipg-dmg"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07093814","nct07589257"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Guangzhou","country":"CN","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/guangzhou-virotech/","neighbours":{"cancer":[{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"trial":[{"id":"nct07093814","kind":"trial","name":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","route":"/trials/nct07093814/"},{"id":"nct07589257","kind":"trial","name":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma","route":"/trials/nct07589257/"}]}}